Global health experts appointed to judge Aster Guardians Global Nursing Award 2025, to be held in Dubai
Over 100,000+ registrations have been received from nurses from 199 countries; a 28% growth from the 3rd edition of the award which had received 78,000+ registrations
Aster Guardians Global Nursing Award 2025 will be held in Dubai, UAE on May 26, 2025.
Dubai – Aster DM Healthcare, one of the largest integrated healthcare provider in the GCC and India, has unveiled the distinguished Grand Jury for the Aster Guardians Global Nursing Award 2025 in Dubai, UAE. This esteemed panel comprises of five leading healthcare experts: Prof. Sheila Tlou, Co-Chairperson of the Global HIV Prevention Coalition, Botswana, Special Ambassador of the African Leaders Malaria Alliance and Former Minister of Health, Botswana; Prof. James Buchan, Adjunct Professor at the WHO Collaborating Centre, University of Technology, Sydney, and Editor Emeritus of the Human Resources for Health Journal; Dr. Peter Carter, OBE Awardee and Independent Healthcare Consultant, Former CEO Central & Northwest London, NHS and Former CEO of Royal College of Nursing, UK; Dr. Niti Pall, President Elect at International Diabetes Federation, Senior Consultant at AXA EssentiAll, France and Board Chair of Harbr & Managing Director of Health4all Advisory, UK and Mr. Vishal Bali, Executive Chairman of Asia Healthcare Holdings & Senior Advisor, TPG Growth, and General Council Member, Neonates Foundation of India.
Reflecting on the remarkable entries this year, Dr Azad Moopen, Founder Chairman, Aster DM Healthcare said, "As we approach the 4thedition of Aster Guardians Global Nursing Awards, it is inspiring to witness the platform's evolution and its profound impact on the global nursing community. This year has seen an exceptional response from nurses worldwide, with over 100,000 registrations pouring in from 199 countries. The task ahead for our esteemed panel of judges is both exciting and challenging, as they shortlist 10 finalists of accomplished nurses making significant contributions in their respective fields and communities. One of these outstanding nurses will win the prestigious award, accompanied by a prize fund of USD 250,000.'
'We are thankful to our Grand Jury members who have believed in the cause and supported the initiative over the years, shaping it's growth journey. I am also excited to welcome Mr. Vishal Bali, Executive Chairman of Asia Healthcare Holdings, to the Grand Jury for this edition. With his vast experience in transforming healthcare systems and his dedication to advancing global healthcare, he brings invaluable expertise and a unique perspective to this prestigious panel' he added.
Mr. Vishal Bali, who joins the Grand Jury for Aster Guardians Global Nursing Award this year, brings over 30 years of global healthcare leadership and a deep commitment to advancing excellence in patient care, making him a distinguished addition to the panel.
On joining the Grand Jury for AGGNA 2025, he commented "Nursing is a combination of intelligence, care and compassion. Nurses symbolise positivity, hope and change. These exceptional individuals are a critical part of our society as they devote themselves to the well-being of others, passionately helping and supporting their patients. They are sympathetic and empathetic. The Aster Guardians Global nursing award is an outstanding initiative to recognise and celebrate nurses who have made a career long contribution to nursing practice, resulting in a legacy of improved healthcare outcomes for individuals, communities and the wider global population. I am thrilled to be a part of this grand jury.'
Professor Sheila Tlou, a former Minister of Health of Botswana, has shaped national nursing and medical education programs. She commented 'As a lifelong advocate for healthcare equity and nursing education, I have seen the critical role nurses play in transforming lives. Being a part of the Aster Guardians Global Nursing Award's Grand Jury once again, I am continually inspired by the extraordinary work nurses do across the world, often in the most challenging circumstances. This platform is a testament to their invaluable contributions to global healthcare.'
Professor James Buchan, a seasoned policymaker and health systems expert, serves as an Adjunct Professor at the WHO Collaborating Centre, University of Technology, Sydney, and is the Editor Emeritus of the Human Resources for Health Journal. He commented 'Nurses are the backbone of healthcare systems worldwide, providing essential care and leadership in times of crisis and beyond. Having been on the jury since the inception of the awards, I have witnessed firsthand the incredible stories of innovation, perseverance, and impact from nurses in every corner of the world. This award is a vital initiative that not only celebrates their contributions but also elevates the profession's visibility and influence on healthcare policy and delivery.'
Dr. Peter Carter, Former CEO Central & Northwest London, NHS, former CEO of the Royal College of Nursing UK and an independent healthcare consultant, boasts diverse experience, holding prestigious fellowships and receiving honors such as the OBE for his NHS service. Since his tenure at the RCN, he has worked nationally and internationally. He commented ' Throughout my career, I have had the privilege of working with outstanding nurses whose skills and dedication transform healthcare. Recognizing and rewarding excellence in nursing is crucial, and the Aster Guardians Global Nursing Award does just that – celebrating those who go above and beyond to advance patient care and the profession itself.'
Dr. Niti Pall, the President Elect at International Diabetes Federation, Senior Consultant EssentiAll, France and Board Chair of Harbr & Managing Director of Health4all Advisory, UK, is a visionary clinical leader with a passion for delivering quality primary care. While practicing in Birmingham, UK, Dr. Pall has made impactful contributions to healthcare in 44 countries. She said ' Innovation in healthcare is impossible without the contributions of nurses, who are at the heart of patient-centered care. Recognizing their role in improving health outcomes and pioneering new approaches is crucial. As a returning jury member, I have seen extraordinary examples of nurses reshaping healthcare with their passion and commitment. It is an honour to once again be a part of this initiative that shines a spotlight on their invaluable work."
Aster has appointed Ernst & Young LLP (EY) as 'Process Advisors' to independently review the applications based on the defined eligibility criteria, moderate evaluation of the entries by an independent panel of experts and present a list of shortlisted candidates to the Grand Jury to determine the winner.
About Aster DM Healthcare FZC in GCC
Founded in 1987 by Dr. Azad Moopen, Aster DM Healthcare is a leading integrated healthcare provider, with a strong presence across 5 countries in the GCC and Jordan. Aster is committed to the vision of providing accessible and high-quality healthcare, from primary to quaternary services, with its promise of 'We will treat you well'. The organisation's robust integrated healthcare model includes 15 hospitals, 122 clinics, and 313 pharmacies in GCC serving all segments of the society through three differentiated brands: Aster, Medcare and Access. Aster consistently adapts to meet the evolving needs of patients, ensuring access to quality healthcare through both physical and digital channels which is exemplified with the launch of the region's first healthcare super app, myAster.
About Aster DM Healthcare Limited, India
Aster DM Healthcare Limited is one of the largest healthcare service providers operating in India with a strong presence across primary, secondary, tertiary, and quaternary healthcare through 19 hospitals with 5,128 beds, 13 clinics, 203 pharmacies (Operated by Alfaone Retail Pharmacies Private Limited under brand license from Aster), and 254 labs and patient experience centers across 5 states in India, delivering a simple yet strong promise to different stakeholders: 'We'll Treat You Well.'
For more information about us, please contact:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Zawya
a day ago
- Zawya
Aster Volunteers UAE recycles 750 kgs of e-waste in 4th collection drive
To date, the initiative has cumulatively recycled 1,998 kgs of e-waste over the four editions. Partnered with E-Scrappy and engaged Asterians in collecting e-waste from nearby shops and homes, demonstrating community involvement and support. A similar activity has been initiated across Qatar, Oman, KSA and India. UAE: Aster Volunteers UAE, the global CSR arm of Aster DM Healthcare, recently organized an impactful 4th E-Waste Collection Drive as part of the 'Aster Green Choices initiative', reinforcing Aster DM Healthcare's unwavering commitment to environmental sustainability. Collection boxes were strategically placed in nine Aster units across the UAE, including Aster Jubilee Medical Centre Bur Dubai, Aster Hospital Mankhool, Aster Hospital Qusais, Aster Hospital Sharjah, Medcare Orthopedics and Spine Hospital, Medcare Al Safa, Aster Clinic Al Warqa, Aster Corporate Office Al Diyafah, Aster Retail Warehouse – Dubai Investment Park, and Aster Cedars Hospital & Clinic, Jebel Ali. Additionally, Medcare Royal Specialty Hospital Qusais and Medcare Hospital Sharjah supported the initiative by contributing some e-waste. The drive resulted in the recycling of 750 kgs of e-waste in collaboration with E-Scrappy. To date, the initiative has cumulatively recycled 1,998 kgs of e-waste over the four editions. The drive not only highlighted the importance of proper e-waste disposal but also educated the public on the environmental impact of electronic waste, encouraging more sustainable practices across the UAE. Over the years, the initiative has successfully recycled 496 kgs of e-waste in 2020, 318 kgs in 2023, 434 kgs in 2024 and now 750 kgs in 2025. Asterians from various units played a crucial role by collecting e-waste from nearby shops and bringing electronic waste from their homes to designated collection boxes. The collected e-waste was responsibly recycled by E-scrappy, who issued a Green Certificate to Aster Volunteers UAE, underscoring their commitment to environmental management. Dr. Azad Moopen, Founder Chairman, Aster DM Healthcare, commented on the initiative, stating, 'Our commitment to environmental sustainability continues to be a core pillar of Aster's mission, guided by our ESG framework and alignment with 10 of the 17 UN Sustainable Development Goals. Aligned with the spirit of World Environment Day, with each edition of the E-Waste Collection Drive, we build greater awareness about the importance of responsible e-waste disposal and foster a culture of recycling within our communities. The success and continued growth of this initiative reaffirm our belief that collective action can drive meaningful environmental impact. Alongside efforts like tree plantations, indoor and seed plant distributions, and clean-up drives, the E-Waste Collection Drive reflects our enduring dedication to a greener, more sustainable future.' The E-Waste Collection Drive is part of Aster DM Healthcare's broader environmental sustainability strategy, which includes other countries like Qatar, KSA, Oman, and India. The company's long-term goals focus on mitigating the environmental impact of toxins leached from buried metals, ensuring the proper disposal and recycling of e-waste. Over the last few years, Aster Volunteers has emerged into a global movement driven by over 85,000 volunteers who have impacted over 6.5 million lives. Aster DM Healthcare GCC achieved a significant reduction of 541 tCO2e in net greenhouse gas emissions through the integration of solar energy sources, including 1,340,000 KWh of solar energy as on 31st March 2024. The company also excelled in waste management, recycling 64,871 kilograms of waste, including 3,992 kilograms of plastic waste, 2,835 kilograms of paper waste, and 434 kilograms of e-waste. The organization prioritizes waste segregation at the source, enabling efficient recycling of biomedical, plastic, food, metals, paper, and cardboard waste. Aster's Annual ESG Report for FY 23-24 highlighted a reduction of 1,769 KL in water consumption across nine hospitals. Social initiatives under Aster Volunteers have significantly contributed to community health, disaster aid, and social empowerment programs. Aster DM Healthcare, one of the largest integrated healthcare providers in the GCC, has received three prestigious awards from the Dubai Chamber of Commerce and Arabia CSR Awards for its sustainability, corporate social responsibility (CSR), and community initiatives. Recognized with the 'Advanced CSR Label for 2022' by the Dubai Chamber, Aster has excelled in Workplace, Marketplace, Community, and Environment impact areas for four consecutive years. The company integrates 10 UN Sustainable Development Goals (UN SDGs) into its ESG policies through initiatives like Aster Volunteers, impacting communities globally. Aster also signed the Action Declaration on Climate Policy Engagement at COP27 and was the only Middle Eastern and Indian company listed among Corporate Knights' Global 100 sustainable companies for 2022, showcasing its commitment to building sustainable organizations. Looking ahead, Aster DM Healthcare aims to continue its commitment to environmental sustainability by organizing more e-waste collection drives and other green initiatives. The organization's long-term goals include reducing carbon emissions, increasing the use of renewable energy, and promoting sustainable practices across all its operations. About Aster Volunteers, the global CSR programme of Aster DM Healthcare Launched in 2017, Aster Volunteers serves as the global CSR arm of Aster DM Healthcare. This initiative embodies the spirit of giving back to society and has touched the lives of over 6.5 million people through various programs with more than 85,000 registered volunteers. Key activities include disaster relief efforts, mobile medical services, free or subsidized surgeries for the needy, medical camps, blood donation drives, and health awareness campaigns. Aster Volunteers focuses on sustainable and impactful solutions, particularly in women's empowerment, education, and social upliftment. For more information about us, please contact:
Web Release
2 days ago
- Web Release
Aster Volunteers UAE Recycles 750 Kgs of E-Waste in 4th Collection Drive
Aster Volunteers UAE, the global CSR arm of Aster DM Healthcare, recently organized an impactful 4th E-Waste Collection Drive as part of the 'Aster Green Choices initiative', reinforcing Aster DM Healthcare's unwavering commitment to environmental sustainability. Collection boxes were strategically placed in nine Aster units across the UAE, including Aster Jubilee Medical Centre Bur Dubai, Aster Hospital Mankhool, Aster Hospital Qusais, Aster Hospital Sharjah, Medcare Orthopedics and Spine Hospital, Medcare Al Safa, Aster Clinic Al Warqa, Aster Corporate Office Al Diyafah, Aster Retail Warehouse – Dubai Investment Park, and Aster Cedars Hospital & Clinic, Jebel Ali. Additionally, Medcare Royal Specialty Hospital Qusais and Medcare Hospital Sharjah supported the initiative by contributing some e-waste. The drive resulted in the recycling of 750 kgs of e-waste in collaboration with E-Scrappy. To date, the initiative has cumulatively recycled 1,998 kgs of e-waste over the four editions. The drive not only highlighted the importance of proper e-waste disposal but also educated the public on the environmental impact of electronic waste, encouraging more sustainable practices across the UAE. Over the years, the initiative has successfully recycled 496 kgs of e-waste in 2020, 318 kgs in 2023, 434 kgs in 2024 and now 750 kgs in 2025. Asterians from various units played a crucial role by collecting e-waste from nearby shops and bringing electronic waste from their homes to designated collection boxes. The collected e-waste was responsibly recycled by E-scrappy, who issued a Green Certificate to Aster Volunteers UAE, underscoring their commitment to environmental management. Dr. Azad Moopen, Founder Chairman, Aster DM Healthcare, commented on the initiative, stating, 'Our commitment to environmental sustainability continues to be a core pillar of Aster's mission, guided by our ESG framework and alignment with 10 of the 17 UN Sustainable Development Goals. Aligned with the spirit of World Environment Day, with each edition of the E-Waste Collection Drive, we build greater awareness about the importance of responsible e-waste disposal and foster a culture of recycling within our communities. The success and continued growth of this initiative reaffirm our belief that collective action can drive meaningful environmental impact. Alongside efforts like tree plantations, indoor and seed plant distributions, and clean-up drives, the E-Waste Collection Drive reflects our enduring dedication to a greener, more sustainable future.' The E-Waste Collection Drive is part of Aster DM Healthcare's broader environmental sustainability strategy, which includes other countries like Qatar, KSA, Oman, and India. The company's long-term goals focus on mitigating the environmental impact of toxins leached from buried metals, ensuring the proper disposal and recycling of e-waste. Over the last few years, Aster Volunteers has emerged into a global movement driven by over 85,000 volunteers who have impacted over 6.5 million lives. Aster DM Healthcare GCC achieved a significant reduction of 541 tCO2e in net greenhouse gas emissions through the integration of solar energy sources, including 1,340,000 KWh of solar energy as on 31st March 2024. The company also excelled in waste management, recycling 64,871 kilograms of waste, including 3,992 kilograms of plastic waste, 2,835 kilograms of paper waste, and 434 kilograms of e-waste. The organization prioritizes waste segregation at the source, enabling efficient recycling of biomedical, plastic, food, metals, paper, and cardboard waste. Aster's Annual ESG Report for FY 23-24 highlighted a reduction of 1,769 KL in water consumption across nine hospitals. Social initiatives under Aster Volunteers have significantly contributed to community health, disaster aid, and social empowerment programs. Aster DM Healthcare, one of the largest integrated healthcare providers in the GCC, has received three prestigious awards from the Dubai Chamber of Commerce and Arabia CSR Awards for its sustainability, corporate social responsibility (CSR), and community initiatives. Recognized with the 'Advanced CSR Label for 2022' by the Dubai Chamber, Aster has excelled in Workplace, Marketplace, Community, and Environment impact areas for four consecutive years. The company integrates 10 UN Sustainable Development Goals (UN SDGs) into its ESG policies through initiatives like Aster Volunteers, impacting communities globally. Aster also signed the Action Declaration on Climate Policy Engagement at COP27 and was the only Middle Eastern and Indian company listed among Corporate Knights' Global 100 sustainable companies for 2022, showcasing its commitment to building sustainable organizations. Looking ahead, Aster DM Healthcare aims to continue its commitment to environmental sustainability by organizing more e-waste collection drives and other green initiatives. The organization's long-term goals include reducing carbon emissions, increasing the use of renewable energy, and promoting sustainable practices across all its operations.
Arabian Post
3 days ago
- Arabian Post
MediLink Therapeutics Taps Major Banks for Hong Kong Float
MediLink Therapeutics Ltd. is preparing to launch an initial public offering in Hong Kong, having secured China International Capital Corp., JPMorgan Chase & Co. and Morgan Stanley as its lead advisers, according to people with knowledge of the matter. The move comes as the clinical-stage biotech firm seeks to capitalise on growing investor interest in advanced tumour-targeting therapies and consolidate its platform of antibody‑drug conjugates. Founded in 2020 and headquartered in Suzhou with R&D operations in Shanghai and Boston, MediLink has developed a proprietary ADC technology known as TMALIN®. The platform facilitates precise delivery of cytotoxic agents to tumour cells, with the intention of widening therapeutic windows for solid tumour treatments. Its pipeline includes programs that have advanced to clinical stages in both China and the United States, supported by a Series B financing round of approximately USD 70 million in 2022. MediLink's strategic engagement of three underwriters reflects heightened confidence in anchor investors and broader syndication. China International Capital Corp. brings deep roots in Chinese capital markets and extensive IPO experience in the biotech sector. JPMorgan and Morgan Stanley add global banking heft and access to international investors. ADVERTISEMENT CICC itself is emerging as a top-tier sponsor for Hong Kong listings. It led or co-led 19 IPOs for Chinese corporates last year, raising USD 3.84 billion, positioning it as a dominant force amid market revival. The engagement of internationally renowned banks alongside CICC is likely aimed at boosting MediLink's valuation and widening investor interest both locally and abroad. While IPO details remain confidential, analysts suggest MediLink could seek a valuation in the mid‑to‑high hundreds of millions of dollars. That would reflect both the advanced stage of its pipeline and prevailing market multiples for ADC developers. Comparable biotech flotations in Hong Kong and the U.S. have reflected growing appetite for oncology-focused platforms. Alongside listing ambitions, MediLink continues to advance its clinical and licensing goals. In March it unveiled preclinical data at the American Association for Cancer Research annual meeting; earlier in the year it received FDA clearance for its IND application for YL217, its lead candidate. YL201, another programme, received Breakthrough Therapy Designation in January for treatment of recurrent/metastatic nasopharyngeal carcinoma. The company has also pursued strategic licensing agreements with global pharmaceutical firms to expand development and commercialisation capabilities. A licensing deal under discussion ahead of the IPO is believed aimed at enhancing distribution reach while reinforcing MediLink's balance sheet. The IPO effort is part of a broader resurgence in biotech listings in Hong Kong, where authorities have eased regulations to attract innovation-driven offerings. CICC and other banks have ramped up support for ADC and gene therapy companies, signalling a turning point after a lull in listings. ADVERTISEMENT MediLink's choice of banks aligns with a wider trend: CICC has co-sponsored blockbuster floats including the forthcoming mega‑IPO of CATL, while banks like Goldman Sachs and Morgan Stanley have also participated. In this context, MediLink is positioning itself to tap both deep domestic networks and international capital. Stakeholder sentiment appears optimistic. MediLink's management team, comprised of co‑founders Tony Xue and Jiaqiang Cai alongside C‑suite leaders experienced in drug development and financial strategy, has overseen steady progress in its ADC pipeline and established global partnerships. Jason Li's appointment as CFO in 2023 reportedly strengthened the company's capital market readiness. Market observers highlight challenges ahead. ADC development remains capital-intensive, clinical risks high, and competition fierce among domestic and international peers. Success will hinge on late‑stage data and licensing traction. At the same time, geopolitical tensions and volatility in Hong Kong equity markets may affect investor sentiment. MediLink must also navigate post‑IPO obligations, including regulatory reporting and corporate governance under Hong Kong's Main Board requirements. Mitigating execution risk will be critical, underscoring the role of its chosen bankers in underwriting diligence and market support. Analysts describe the listing as a pivotal moment: it offers the backing to fund Phase II/III efforts while elevating MediLink's corporate profile. For banks, it reinforces Hong Kong's appeal as a biotech capital market when compared with established centres like Nasdaq. With its IPO process underway, MediLink now awaits market timing and regulatory clearances before formally filing a prospectus. The company is expected to continue advancing clinical data, strengthening licensing ties, and preparing investor materials aligned with regulatory requirements.
